Despite the known role of inflammation in atherosclerosis, interventions beyond statins that address this mechanism have been either unsuccessful or plagued with extreme costs and/or intolerable side effects. As a relatively low-cost and acceptably-tolerated medication, colchicine would be a practical choice to target the inflammatory nature of atherosclerosis and has shown promise in previous studies. This blog discusses the recent publication of the Colchicine Cardiovascular Outcomes Trial (COLCOT) and the implications for colchicine to reduce ischemic events.
